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Abstract. – OBJECTIVE: The aim of this
study was to analyze the women with high grade
vaginal intraepithelial neoplasia (HG-VaIN), in or-
der to identify a subset of women at higher risk
of progression to invasive vaginal cancer.
PATIENTS AND METHODS: The medical
records of all the women diagnosed with HG-
VaIN, and subsequently treated, from January
1995 to December 2013 were analyzed in a multi-
centre retrospective case series. The rate of pro-
gression to invasive vaginal cancer and the po-
tential risk factors were evaluated.
RESULTS: 205 women with biopsy diagnosis
of HG-VaIN were considered, with a mean follow
up of 57 months (range 4-254 months). 12 cases
of progression to vaginal squamocellular cancer
were observed (5.8%), with a mean time interval
from treatment to progression of 54.6 months
(range 4-146 months). The rate of progression
was significantly higher in women diagnosed
with VaIN3 compared with VaIN2 (15.4% vs.
1.4%, p < 0.0001). Women with HG-VaIN and with
previous hysterectomy showed a significantly
higher rate of progression to invasive vaginal
cancer compared to non-hysterectomised
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women (16.7% vs. 1.4%, p < 0.0001). A higher
risk of progression for women with VaIN3 and
for women with previous hysterectomy for cervi-
cal HPV-related disease was confirmed by multi-
variable logistic regression analysis.
CONCLUSIONS: A higher rate of progression
to vaginal cancer was reported in women diag-
nosed with VaIN3 on biopsy and in women with
previous hysterectomy for HPV-related cervical
disease. These patients should be considered at
higher risk, thus a long lasting and accurate fol-
low up is recommended.
Key Words:
Vaginal Intraepithelial neoplasia, VaIN, Vaginal cancer.
Introduction
Vaginal Intraepithelial Neoplasia (VaIN) is a
rare histological lesion of the vaginal epithelium,
typically diagnosed through a colposcopy-guided
biopsy of suspicious areas after an abnormal re-
ferring pap smear. Its development is due to a
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persistent high risk human papillomavirus (HPV)
infection1,2. Multiple sexual partners and early
stage at sexual debut3, smoking1,4 and immuno-
suppression5, increasing the likelihood of HPV
infection, are described as further risk factors.
These lesions are characterised by dysplastic
changes in the vaginal epithelium, without stro-
mal invasion2 and, accordingly to the depth of
the tissue involved, they are classified in VaIN1
(mild dysplasia), VaIN2 and VaIN3 (moderate
and severe dysplasia, respectively).
VaIN1, also defined “low-grade VaIN”, can be
considered as the transient expression of HPV in-
fection, with no potential of progression to vaginal
cancer and with a high rate of spontaneous regres-
sion6,7, while VaIN3 can be properly considered
“high-grade VaIN” (HG-VaIN), due to its poten-
tial progression to vaginal cancer. The VaIN2 cat-
egory is not a reproducible histopathologic catego-
ry among pathologists8,9 and the risk of progres-
sion for lesions classified as VaIN2 is supposed to
be intermediate between VaIN1 and VaIN39.
However, since the real potential of progression to
invasive cancer of VaIN2 is still discussed, some
Authors encompass VaIN2 in the HG-VaIN cate-
gory7,10-12. Globally HG-VaIN account for only
0.4% of female lower genital tract intraepithelial
lesions13,14, with an incidence from 0.2 to 2 per
100,000 women/year8. Therefore, HG-VaIN is a
rare condition and its natural history is not well
known, as well as its real potential to progress to-
wards invasive squamous cell vaginal cancer6,7,10-
12,15-17
. Moreover, even because of the lack of a
complete knowledge of its natural history, the op-
timal management of HG-VaIN actually remains a
“therapeutic dilemma”8. Various treatment modal-
ities have been employed with varying success
among women with HG-VaIN16,18; current prac-
tice include immediate surgical treatment with ex-
cisional or ablative procedures.
To our knowledge, only few studies analyzed
the rate of invasive vaginal cancer in women
treated for HG-VaIN and a rate of progression to
cancer from 2% to 7% was reported10,11,16,17.
The aim of this study was to analyse the rate
of progression to cancer in women with HG-
VaIN, in order to identify a subset of women at
higher risk.
Patients and Methods
This study was sponsored by the Italian So-
ciety of Colposcopy and Cervico-Vaginal
Pathology (SICPCV) and seven hospitals in the
central and northern Italy participated to data
collection.
All the women with histological diagnosis of
VaIN2 and VaIN3 consecutively referred to the
institutions involved, from January 1995 to De-
cember 2013, were considered. These women
were diagnosed with HG-VaIN through biopsy
of suspicious areas detected on colposcopy after
an abnormal pap-smear. Colposcopic examina-
tions were recorded accordingly to the 2011 re-
vised colposcopic terminology of the Internation-
al Federation for Cervical Pathology and Col-
poscopy (IFCPC)19. The colposcopies performed
before the introduction of the 2011 IFCPC termi-
nology were revised accordingly.
All the colposcopies and the vaginal biopsies
were performed by gynecologic oncologists with
particular expertise in the diagnosis and manage-
ment of pre-invasive and invasive lesions of the
lower female genital tract. Similarly all the biop-
sies and the surgical specimens obtained after
surgical excision procedures were analyzed by
pathologists with particular expertise in the pre-
invasive and invasive lesions of the female lower
genital tract.
All the women considered were diagnosed
with HG-VaIN for the first time, thus women
with previous diagnosis and/or treatments for
HG-VaIN were excluded, in order to avoid po-
tential confounders. Similarly, women with syn-
chronous squamocellular cervical invasive can-
cer (SCC) or vaginal invasive cancer were ex-
cluded.
Patients were identified by searching the clini-
cal databases of the institutions involved, and the
medical records of women fulfilling the study
in0clusion criteria were analyzed in a retrospec-
tive case series. Data obtained included informa-
tion regarding pertinent medical and surgical his-
tory, sociodemographic characteristics of each
woman and clinical outcome at follow up.
Women diagnosed with HG-VaIN were treat-
ed with ablative therapies (CO2-laser ablation,
electrofulguration, radiotherapy, photodynamic
therapy – PDT – or topic 5-FU) or with excision-
al procedures (CO2-laser excision or CO2-laser
skinning colpectomy, radio-frequency excision,
cold-knife local excision or traditional cold-knife
upper colpectomy, with vaginal or abdominal ac-
cess).
After the initial diagnosis of HG-VaIN and the
subsequent first line treatment, all the women un-
derwent a routine follow up with pap test and
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colposcopy every 6 months for the first 2 years,
then yearly. From 2010 a HR-HPV test was per-
formed 6 or 12 months after the first line proce-
dure, depending on the internal guidelines of
each institution.
In case of gynecologic symptoms (e.g. vaginal
bleeding) a prompt gynecologic evaluation, was
performed. Suspicious areas detected during fol-
low up colposcopic examinations were biopsied.
Progression is defined as the histopathological
evidence of invasion after the first line treatment.
All the women with progression to vaginal in-
vasive cancer, fulfilling the other study inclu-
sion/exclusion criteria were considered, regard-
less the length of follow up. In case of negative
follow up, only women with a minimum follow
up of six months were included in the analysis.
Each woman with histopathological evidence
of HG-VaIN during the routine follow up exami-
nations, underwent one or more additional treat-
ments as required.
Statistical Analysis
Statistical analysis was performed using IBM
SPSS version 22.0 (IBM Corporation, Armonk,
New York, USA). The χ2 testing, the Fisher ex-
act test and Mann Whitney U test were used, as
appropriate, to evaluate associations. A p-value <
.05 was considered as statistically significant.
Institutional Review Board approval (CRO
IRB n. 17/2013) was obtained.
Results
From January 1995 to December 2013, 288
women were diagnosed with HG-VaIN for the
first time in the institutions involved in the pre-
sent study. Among them, 205 women fulfilling
the study inclusion criteria, were considered. The
mean age of these women was 46 years old (SD
± 13.7, range 19-78 years) and, in particular, 92
women (44.9%) were in post-menopausal status.
Tobacco use was reported in 42 women of 163
on which this datum was available (25.8%) and
HIV infection was present in 14 cases (6.8%).
Previous diagnosis of HPV-related cervical dis-
ease (CIN, carcinoma in situ or invasive cancer)
was reported in 95 cases (46.3%). Sixty women
(29.3%) previously underwent hysterectomy; in
particular hysterectomy was performed because
of CIN/CIS or invasive cervical cancer in 45 cas-
es. In the remaining 15 cases the hysterectomy
was performed because of benign conditions or
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non HPV-related malignancies. However, two of
these patients showed a history of CIN before the
hysterectomy.
In the whole study cohort, 140 women were
diagnosed with VaIN2 on biopsy (68.3%), while
the remaining 65 women were diagnosed with
VaIN3 (31.7%).
The first line treatments performed after the
diagnosis of HG-VaIN in the study population
are reported in Table I.
A mean follow up of 57 months (range 4-254
months) after the first-line treatment was report-
ed.
Twelve cases of progression to vaginal inva-
sive cancer were observed in the whole study co-
hort (5.8%), with a mean time interval from
treatment to progression of 54.6 months (range
4-146 months).
Women with progression to vaginal cancer
were older (57.7 ± 14.5 vs 45.3 ± 13.3 years old,
p = 0.002) and more likely to be in menopause
(75% vs. 42.5%, p = 0.001).
In 2 cases, the progression to vaginal invasive
cancer was observed after an initial diagnosis of
VaIN2 (with 4 and 38 months of follow up, re-
spectively), while in the remaining 10 cases the
initial diagnosis on biopsy was VaIN3. Thus in
women with VaIN3 compared to women with
VaIN2, the rate of progression to invasive dis-
ease was significantly higher (15.4% vs. 1.4%, p
< 0.0001).
In ten cases, the progression to vaginal cancer
was observed in hysterectomized women and, in
particular, in 9 of these cases, the hysterectomy
was performed for HPV-related cervical disease
(CIN/CIS or SCC). Moreover, in these 9 women,
the vaginal dysplastic lesion leading to invasive
carcinoma developed in the vaginal cuff or in the
Ablative procedures n = 120
CO2-laser ablation 80
Electrofulguration 37
Radiotherapy 1
Photodynamic therapy 1
Topic 5-FU 1
Excisional procedures n = 85
CO2-laser excision 51
Radiofrequency excision 30
Cold knife upper colpectomy 4
Table I. First line therapy after diagnosis of HG-VaIN in
the study population (n = 205).
lateral recesses. In one case, the progression to
vaginal invasive cancer was detected after hys-
terectomy for benign condition, but this patient
had a history of HR-HPV related disease of the
uterine cervix.
The progression to invasive vaginal cancer
was observed in 10 women up 60 with previous
hysterectomy, while only 2 cases of progression
among the remaining 145 women were reported
(16.7% vs. 1.4%, p < 0.0001). Considering only
the 45 women with previous hysterectomy for
CIN/SCC, the progression to invasive cancer was
reported in 20% of cases (9/45 cases).
All women with progression to invasive vagi-
nal cancer had a history of HPV-related cervical
diseases and the risk of progression was signifi-
cantly higher in women with previous CIN or
SCC (12.6% vs. 0%, p < 0.0001).
The time of progression appear to be indepen-
dent from the grade of VaIN or previous hys-
terectomy for CIN or SCC (p > 0.6 Mann Whit-
ney U test).
The clinical and histopathological characteris-
tics of women with progression to invasive vagi-
nal cancer are reported in Table II.
By multivariate logistic regression analysis
(Table III), only previous hysterectomy for
CIN/SCC and VaIN3 on biopsy showed an inde-
pendent significant association with the progres-
sion to invasive vaginal cancer (OR = 5.61, 95%
CI 1.28-24.63 and OR = 5.61, 95% CI 1.06-
29.76, respectively).
Discussion
Vaginal cancer is a rare disease, accounting
for less than 2% of all the gynecologic malignan-
cies with an incidence of approximately 3000
new cases per year in the United States20. Ap-
proximately 80-90% of primary vaginal cancers
are squamous cell carcinomas21 and most of them
seems to be preceded by HG-VaIN22. However,
even the HG-VaIN is quite rare and, therefore, its
natural history, and especially its true malignant
potential of progression to invasive cancer, is ac-
tually on debate6,10,11,21.
In the present series, during a long follow up
period, a overall rate of progression to vaginal
cancer of 5.8% was reported; this datum appear
to be similar to those of the few previous pub-
lished studies, reporting a rate of progression to
cancer from 2% to 7%10,11,16,17. However, the
factors influencing the risk of progression of
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HG-VaIN to cancer are still not known and, dif-
ferently from other previous studies, we tried to
stratify the risk of progression to cancer in differ-
ent subsets of patients.
In our series a significantly higher rate of
progression to cancer emerged in women previ-
ously diagnosed with VaIN3 compared to
women with VaIN2 (15.4% vs. 1.4%, p <
0.0001). This datum appear of particular inter-
est if we consider the actual debate on the nat-
ural history of HG-VaIN. VaIN2 and VaIN3
have been both considered as HG-VaIN by sev-
eral authors7,10-12 just because of their potential
progression towards vaginal cancer. However,
some Authors don’t encompass VaIN2 in this
category, considering only VaIN3 as the true
precursor of invasive vaginal cancer8,9.
In our cohort we observed a over 10 times
higher risk of progression in women with VaIN3
compared to women with VaIN2; for this reason,
in our opinion, VaIN3 should be considered as
the true precursor of vaginal cancer.
A previous hysterectomy seems to be another
important risk factor for progression to cancer
and a higher risk of progression in these women
emerged, especially in women with hysterectomy
for CIN/CIS/SCC, as confirmed by multivariable
logistic regression.
A possible interpretation of this datum is that,
in women with HPV-related cervical disease,
vaginal dysplastic lesions can coexist. After hys-
terectomy these lesions could spread in the con-
text of the scar on the cuff, remaining clinically
undetectable for long time, and thus invasive
cancer can grow.
Therefore, among patients with HG-VaIN,
hysterectomized women with previous HPV-re-
lated disease of the lower genital tract should be
considered a higher risk subset of patients. In
this cases one of the most important issue is the
possibility of occult invasive disease at the time
of diagnosis of HG-VaIN. For this reason, in
these patients, an accurate colposcopic evalua-
tion with biopsy is mandatory and an excisional
treatment of HG-VaIN should be preferred, in or-
der to detect otherwise occult invasive lesions.
In the present study, we observed an extreme-
ly variable time interval from treatment for HG-
VaIN towards progression to cancer, with one
cases of progression occurred more than 12 years
after the first treatment. Therefore, we recom-
mend a close follow up every six months for the
first two years, then yearly, for at least fifteen
years.
From 2010 we have introduced the HR-HPV
test in the follow up of these patients, but the po-
tential correlation with the risk of progression to
cancer is unclear. Since the HG-VaIN and the
vaginal squamocellular cancer are related to a
persistent HR-HPV infection1,2, a negative HR-
HPV test could be helpful in reducing the need
for follow up in these patients. However, the
negative predictive value of the test seems to be
very low, especially when the lesion do not reach
the mucosal surface8 and further studies are
needed before we can make specific recommen-
dations about the use of HR-HPV test in the fol-
low up of women treated for HG-VaIN.
In 2 cases the progression to invasive cancer
was detected only 4 months after the first line
treatment. The routine follow up at our institu-
tions include a gynecologic examination with cy-
tology and colposcopy 6 months after the first
line treatment. These 2 women were examined
before the scheduled follow up because they re-
ferred vaginal bleeding. They were both treated
with electrosurgical ablation and probably the
rapid progression to cancer can be considered ex-
pression of insufficient depth of ablation during
treatment; it is possible to suppose that, in these
cases, the vaginal dysplastic lesions harbored oc-
cult invasive disease.
The retrospective nature of this study limited
the clinical data to those already collected in the
Progression to No progression to Adjusted*
vaginal cancer invasive vaginal cancer Odds Ratio
Characteristics n = 12 (5.8%) n = 193 (94.2%) (95% CI) p-value
Previous hysterectomy for CIN/SCC 9 (75%) 36 (18.6%) 5.61 (1.28-24.63) 0.02
VaIN3 on biopsy 10 (83.3%) 55 (28.5%) 5.61 (1.06-29.76) 0.04
Table III. Multivariable logistic regression of risk factors for progression to squamocellular invasive vaginal cancer in women
with biopsy diagnosis of HG-VaIN.
*Adjusted for age, previous hysterectomy, treatment modality and previous HPV-related disease of the lower genital tract.
medical charts and it was not possible to identify
the factors that influenced the choice of treat-
ment modality in all the patients. Some of the
factors considered included location of the le-
sions and multifocality, patients comorbidities as
well as patient’s or physician’s preference. How-
ever, in this study, we analyzed the rate of pro-
gression to cancer in women with HG-VaIN re-
gardless to the treatment performed, even be-
cause HG-VaIN and mostly vaginal cancer are
quite rare.
Thus further studies analyzing the potential
role of different therapeutic strategies in the pro-
gression to invasive disease are needed.
Conclusions
Women with HG-VaIN should always be
carefully evaluated by gynecologic oncologists
with particular expertise in the diagnosis and
management of pre-invasive and invasive le-
sions of the lower female genital tract. A long
lasting and accurate follow up is recommended,
especially in women at higher risk of progres-
sion to invasive vaginal cancer (VaIN3 and
previous hysterectomy for HPV-related cervi-
cal disease).
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